Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success
Shifts Focus To Earlier Program
Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.
